Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8IZP7

UPID:
H6ST3_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8IZP7; Q5W0L0; Q68CW6

BACKGROUND:
The enzyme Heparan-sulfate 6-O-sulfotransferase 3, identified by the unique identifier Q8IZP7, catalyzes the critical transfer of sulfate groups to heparan sulfate. This sulfation process is essential for the functional maturation of heparan sulfate, impacting a wide range of biological activities from cell communication to the regulation of growth factors.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Heparan-sulfate 6-O-sulfotransferase 3 holds significant promise for the development of novel therapeutic approaches. Given its central role in heparan sulfate biosynthesis, targeting this enzyme could lead to innovative treatments for diseases where altered heparan sulfate function is a contributing factor.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.